Concept Strengthens its Assay Development Capabilities With New Hire
Dr Andrew Clifton joins Concept Life Sciences as Head of Bioassay Development and Screening Technologies. Concept Life Sciences offers tailored preclinical services including integrated drug discovery programs. Dr Clifton strengthens the existing industry team at Concept and will be responsible for providing assay development and screening capabilities to support preclinical drug discovery projects from hit finding through to candidate selection.
Andrew has over eighteen years’ experience in both large pharma and biotech through his roles at AstraZeneca and Redx Pharma. Andrew’s expertise is in biochemistry and pharmacology with experience across major drug target classes including a wide variety of enzymes and GPCRs. He has extensive experience of assay development and screening applied to hit finding, hit to lead and lead optimization and has contributed to the delivery of multiple clinical candidates. His therapy area experience includes oncology, inflammation/fibrosis and respiratory. Prior to commencing his pharmaceutical career, Andrew completed his doctoral training with Professor Sir Philip Cohen at the University of Dundee MRC Protein Phosphorylation Unit.
Commenting on his appointment Andrew stated: “I am delighted to be joining Concept Life Sciences at this exciting time in its development. Concept is generally recognized as a leading global provider of preclinical drug discovery services, and I look forward to building our assay development and screening capability to support integrated drug discovery projects. I also look forward to supporting the groups many integrated discovery and development partners, from virtual biotech’s to big pharma.”
Commenting on Dr Clifton’s appointment, Dr Chris Doe, Head of Biology at Concept Life Sciences said: “I am thoroughly delighted to welcome Dr Andrew Clifton to the team. Andrew’s expert knowledge and track record in this field will further strengthen our existing team and underpin our services as a leading UK CRO in Integrated Discovery & Development Services.”
This article has been republished from materials provided by Concept Life Sciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018